The Homo Genius in the Adaptation Phase

In nearly every consultation room in nearly every Western city, on nearly every weekday morning, a person sits across from a physician and tries to explain a set of experiences that have followed them for as long as they can remember, and the physician, working under the time pressure that defines contemporary medicine and trained within a framework that recognizes the symptoms but not the underlying neurology, reaches for a prescription pad and writes something that will dampen the surface signal without ever touching what produced it. The person leaves with a serotonin reuptake inhibitor, or with a benzodiazepine, or with a stimulant, or with some combination of the three, and a year later they are back in the same room asking why nothing has changed at the level of the experience itself, only the volume has been turned down on parts of it, and the parts that were valuable have gone quiet along with the parts that hurt. This is the standard pathway by which a substantial fraction of the autistic adult population in Germany, in the United States, and across the developed world receives its first interaction with the medical system, and it is the standard pathway by which that population is then misdiagnosed, mistreated, and prevented from understanding what is actually going on inside its own nervous system for the better part of a working lifetime.

I want to be careful at the outset, because the topic carries a particular kind of cultural weight in the present moment. Several physicians I count among my friends have remarked over the past few years that autism has begun to function, in certain demographics, as a desired diagnosis, an identity that confers a sense of distinction in a culture that increasingly demands that everybody be distinguishable from everybody else, and there is some truth to this observation, although the truth is less interesting than the observation suggests. The much larger phenomenon, the one that genuinely warrants attention, is the population of people who have lived their entire adult lives undiagnosed or misdiagnosed, who have been told that they suffer from depression, from anxiety disorders, from borderline personality, from chronic fatigue, from a series of vague and shifting psychiatric labels that never quite explain why nothing improves regardless of what is prescribed, and who have spent decades being prescribed pharmaceuticals whose effect on the underlying neurology ranges from negligible to actively harmful. These are the people the present article is written for, and these are the people the cultural conversation around autism, with its current focus on celebrities and self-diagnosis, often manages to overlook entirely.

Neurology and neurobiology are fields I have worked into for close to two decades, alongside the forensic and biological work that constitutes the rest of my professional life, and I want to state plainly at this point that I have come to recognize autistic individuals quickly and reliably across professional contexts, in the way they speak, in the way they move, in the rhythm and the precision of the questions they ask, and not least in the specific cognitive and perceptual abilities they bring to bear on problems that more typical brains find genuinely difficult to approach. I am going to argue, in what follows, that autism is misnamed when it is called a developmental disorder, that the diagnostic infrastructure built around it reflects the anxieties of the institutions doing the diagnosing more than it reflects the biology of the people being diagnosed, and that what we are looking at, when we look at the autistic population, is not a defective version of the typical human brain but a distinct cognitive architecture that is, from the standpoint of evolutionary anthropology, very probably an early sample of what the next phase of human cognition will look like.

What the Numbers Say, and What They Do Not Yet Say

Before we go further, the epidemiology deserves attention, because the discussion that follows depends on a particular reading of why the numbers are doing what they are doing. The Centers for Disease Control and Prevention reported in 2023 that one in thirty-six American children was being identified with autism spectrum condition through the Autism and Developmental Disabilities Monitoring Network, which represented an increase from one in forty-four in the previous reporting period and from one in one hundred and fifty in the year 2000. The Global Burden of Disease analysis, working from a different methodology and a different denominator, estimated that prevalent cases worldwide rose from approximately forty-two million in 1990 to roughly sixty-two million in 2021, with projections reaching seventy-two million by 2045 and the age-standardized prevalence rate expected to peak around 2029. The World Health Organization places the global figure at approximately one in one hundred, with the understanding that this estimate is conservative because case identification in many parts of the world remains limited.

The interpretation of these numbers is where the discipline divides, and the division matters because it determines what gets done in response. One reading, the cautious mainstream reading, attributes the increase primarily to broadened diagnostic criteria, to better case identification, particularly in populations that were historically underdiagnosed such as girls and racial minorities, and to the diffusion of the concept itself into communities that previously lacked any framework for recognizing it. There is genuine truth in this reading, and it accounts for a meaningful portion of the rise. The other reading, the one I find harder to dismiss after working in adjacent fields for as long as I have, is that something is also happening at the level of the population itself, that the prevalence is rising in absolute terms as well as in measured terms, and that the rise reflects a real shift in the distribution of human neurological types, driven by some combination of genetic, environmental, and assortative-mating factors that the field does not yet understand well enough to disentangle cleanly. From an anthropological standpoint, the question is not whether the increase is real, the question is what the increase represents, and the cautious institutional reading is, I suspect, doing some work of reassurance that the underlying data does not actually support.

The Heritability Number, and What It Quietly Tells Us

The genetics of autism are, by the standards of complex neurodevelopmental conditions, unusually well characterized, and the central finding has been remarkably stable across decades of investigation. Heritability estimates from twin studies converge on figures between fifty percent at the low end and ninety percent at the high end, with most contemporary syntheses placing the central estimate around eighty percent, which makes autism one of the most heritable neuropsychiatric conditions in the medical literature, exceeded only by a handful of conditions including schizophrenia and bipolar disorder. The classic concordance figures are striking in their own right: monozygotic twins show concordance rates between sixty and ninety-two percent, while dizygotic twins show rates between zero and ten percent, and these figures have held up across multiple independent studies in different populations and across decades of methodological refinement.

The genetic architecture itself is polygenic and heterogeneous in a way that complicates any simple narrative, with more than one hundred genes identified as contributing risk variants and with the field continuing to discover additional candidates through whole-exome and whole-genome sequencing studies. Among the most consistently implicated are SHANK3, which encodes a synaptic scaffolding protein essential for the formation and maintenance of excitatory synapses, CHD8, a chromodomain helicase whose mutations have been characterized as defining a distinct clinical subtype of autism early in development, SCN2A, encoding a sodium channel critical for neuronal excitability, NLGN3 and NLGN4, encoding neuroligins involved in synaptic adhesion, and a growing list including GRIN2B, SYNGAP1, MECP2, ADNP, DYRK1A, and PTEN, with each gene contributing to either synaptic function, chromatin remodeling, or neuronal connectivity in ways that converge on a small number of biological pathways. De novo mutations, meaning mutations that arise in the affected individual rather than being inherited from either parent, account for an additional portion of cases, and the rate of these de novo mutations has been shown to correlate with paternal age in particular, a finding consistent with the broader observation that older fathers transmit a higher mutational load to their offspring through generations of germline cell divisions.

What I take from this body of evidence, looking at it as someone whose professional life has involved a great deal of population-level biology, is that autism is not a developmental accident, it is not a disease in the conventional sense of an external pathogen attacking a healthy substrate, and it is not the consequence of vaccines, refrigerated mothers, dietary errors, or any of the long succession of environmental scapegoats that have been proposed and disproved over the past several decades. It is a heritable variation in the architecture of the human nervous system, with a clear biological basis at the level of synaptic function and neural connectivity, and the high heritability number is doing important quiet work in the background of any serious discussion of what we are actually looking at when we look at this population.

The Forms It Takes, and Why the Word Spectrum Is Both Right and Misleading

The clinical presentation of autism varies across a range so wide that the term spectrum, while accurate at the level of phenotype, can mislead anyone who imagines a spectrum as a single line along which individuals are arrayed by severity. The reality is closer to a multidimensional space in which different aspects of cognition, sensory processing, language, social orientation, and motor function vary somewhat independently of one another, so that two individuals carrying the same diagnostic label can present in ways that are barely recognizable as members of the same category, and the public imagination, which still defaults to the image of Dustin Hoffman counting toothpicks in Rain Man, captures only one narrow corner of the actual distribution.

The high-functioning end of the distribution, which includes what was historically called Asperger syndrome before that diagnostic category was folded into the broader autism spectrum disorder by the DSM-5 in 2013, is occupied by individuals whose intellectual capacity is at or above population average and whose autistic features manifest primarily in social cognition, in restricted and intense interests, in sensory sensitivities, and in differences in language pragmatics rather than in language structure itself. Many of these individuals are professionally successful, often in fields that reward precision, pattern recognition, and the ability to sustain attention on technical material for long periods, and many of them remain undiagnosed for decades, navigating a social world that does not quite fit them through a combination of intelligence, observation, and exhausting compensatory effort. They are also, as I am about to discuss in some detail, the population most likely to have spent years or decades carrying psychiatric diagnoses that miss the actual structure of what they are dealing with, and being prescribed medications that do not address the underlying biology.

In the middle range of the distribution sit individuals whose autistic features are more prominent and whose adaptive functioning ranges from independent with significant support needs through to requiring structured assistance for many activities of daily living, with cognitive profiles ranging widely and with language development showing varying degrees of typical and atypical features. The lower-functioning end of the distribution, what the recent CDC reporting has begun to call profound autism and what is estimated to constitute roughly twenty-seven percent of the diagnosed population, includes individuals with intellectual disability, with limited or absent verbal communication, with significant sensory and motor differences, and with care needs that extend across the entire lifespan and place very real demands on families, educational systems, and adult services.

I want to be honest about something else, because the romantic narrative around autism has begun to obscure it. Not every autistic person is gifted, not every autistic person carries the savant-like abilities that capture popular attention, and the relationship between autism and exceptional cognitive capacity, while genuine in the parts of the distribution where it appears, is statistical rather than universal. There are autistic individuals whose cognitive profile is unremarkable and there are autistic individuals whose cognitive profile is below the population average, and the discussion that follows about the anthropological significance of this neurology applies to the architecture of the type rather than to the individual variability within it. A serious scientific and ethical engagement with autism has to hold both of these things at once: the genuine cognitive distinctiveness that the type often produces, and the human reality of individuals across the full range of intellectual function and adaptive capacity.

Why the Calm Under Pressure, the Question That Got Me Thinking About All of This

There is a phenomenon I have observed in clinical, forensic, and personal contexts often enough that it stopped seeming coincidental at some point, and the literature on autonomic regulation in autism gives it a coherent biological explanation that I want to lay out here because it changes the way the diagnostic picture looks. The phenomenon is this: in genuine emergencies, in situations where most people experience a flood of autonomic activation that interferes with cognition and decision-making, autistic individuals frequently remain calm, focused, and operationally effective in ways that the surrounding non-autistic population cannot match. This is not a universal pattern, and it is certainly not true of every autistic person under every kind of stress, but it appears often enough in observation that it constitutes a recognizable feature of the type rather than an idiosyncrasy of particular individuals.

The neurobiology that appears to underlie this pattern involves a specific configuration of the autonomic nervous system in many autistic individuals, with elevated baseline sympathetic tone, attenuated parasympathetic reactivity, and a reduced amygdala response to social-evaluative threat that paradoxically protects cognitive function under acute physical or operational stress. The same biology that makes a busy supermarket genuinely overwhelming, with its fluorescent lights and its overlapping conversations and its unpredictable sensory inputs, can in a different kind of crisis render the autistic individual the most useful person in the room, because the social-emotional cascade that paralyzes most people simply does not engage in the same way. The processing remains analytic rather than reactive, the attention remains narrow and deep rather than diffuse and panicked, and the action that emerges from that processing is frequently more adaptive than what the surrounding population produces.

This observation, taken seriously, begins to shift the frame within which autism is conventionally understood. A neurology that produces difficulty in routine social situations but produces unusual competence in genuine crisis is not, on its face, the signature of a developmental disorder, it is the signature of a different optimization, a different set of trade-offs about what to prioritize and what to deprioritize in the construction of a functioning human nervous system. Whether one wants to follow that observation all the way to its anthropological implications, as I will do at the end of this piece, is a separate question, but the observation itself stands on its own, and it deserves more attention than it currently receives in either clinical or popular discussions of the condition.

The PTSD Question, and Why So Many Adult Autistics Look Traumatized

A second observation that has emerged repeatedly in the research literature on adult autism, and that intersects in important ways with the masking phenomenon I will discuss in the next section, is that the symptom profile of many late-diagnosed adult autistics shares a substantial overlap with the symptom profile of complex post-traumatic stress disorder. The exhaustion, the hypervigilance, the difficulty regulating emotional states, the social withdrawal, the dissociative episodes, the sleep disturbance, the chronic somatic complaints, all of these features appear in both populations in ways that have led some clinicians to misdiagnose autism as PTSD and others to misdiagnose PTSD as autism, with the further complication that many autistic adults carry both, the autism as the substrate condition and the trauma as the accumulated consequence of decades of attempting to function in environments that were not built for their nervous system.

The mechanism appears to operate roughly as follows. An autistic child, growing up undiagnosed or with inadequate accommodation, learns through repeated experience that the social and sensory environment around them is unpredictable, frequently overwhelming, and populated by people whose responses to autistic behavior range from puzzled to punitive. The child develops, by necessity, a set of compensatory strategies, the careful watching of social cues that come naturally to neurotypical peers, the deliberate suppression of stimming and other self-regulatory behaviors that would draw negative attention, the conscious modulation of voice and expression and posture into shapes that the surrounding social environment will accept. These compensatory strategies, sustained for years or decades, impose a cumulative metabolic and neurological cost that the autistic adult eventually pays in the form of what the literature now recognizes as autistic burnout, a state of profound exhaustion, regression of previously mastered skills, intolerance of stimuli that were previously manageable, and pervasive depression that resembles classical burnout but operates on a fundamentally different biological substrate.

The autistic burnout literature, which has developed considerably over the past five years through the work of researchers including Dora Raymaker at Portland State University and the AASPIRE collaborative, has begun to document the recovery patterns and the precipitating factors with the kind of rigor that the field had previously reserved for the more visible aspects of the condition. What emerges from this literature is a picture of a population whose long-term psychiatric symptoms are, in a substantial fraction of cases, not primary affective or anxiety disorders but secondary consequences of decades of unsupported masking, and whose treatment with conventional antidepressants and anxiolytics tends to produce limited benefit precisely because the underlying driver is not what those medications are designed to address.

Why Ketamine and Psilocybin Are Producing Results Where Conventional Pharmacology Has Failed

A development of considerable interest over the past several years, and one that has attracted substantial research investment in both academic and commercial settings, is the observation that two compounds operating outside the conventional psychiatric pharmacopoeia have shown unusual promise in addressing some of the most treatment-resistant features of the autistic adult presentation, particularly the social anxiety, the depression, and the rigid cognitive patterns that often accompany the condition in adulthood. The two compounds are ketamine, an N-methyl-D-aspartate receptor antagonist originally developed as an anesthetic, and psilocybin, the principal psychoactive compound in several species of fungi of the genus Psilocybe, which acts as an agonist at the serotonin 5-HT2A receptor.

The mechanistic case for why these compounds might be useful in autism runs through a feature of the autistic brain that has been documented in imaging studies for some years, which is the unusual rigidity of certain large-scale functional networks and the difficulty the autistic brain has in transitioning flexibly between different cognitive and emotional modes. Ketamine, through its effects on glutamatergic signaling and on synaptic plasticity, appears to temporarily increase the flexibility of these networks and to permit changes in patterns of thought and emotion that have, in many cases, been stable for decades. Psilocybin, through its effects on the serotonergic system and on the default mode network, appears to produce a similar kind of temporary reorganization, with the additional feature of producing prosocial effects and reductions in social anxiety that often persist well beyond the acute pharmacological window.

I want to be careful about what is and is not established in this area, because the popular discourse around psychedelic medicine has run somewhat ahead of the evidence and there is a genuine risk of overclaiming. What can be said with reasonable confidence is that conventional pharmacology has done very poorly at addressing the core features of autism, that the medications most commonly prescribed to autistic adults address comorbid features rather than core ones and frequently produce side-effect profiles that the autistic nervous system tolerates poorly, and that the early signals from work on ketamine and psilocybin suggest something genuinely different is happening at the level of network flexibility and synaptic plasticity.

The Screening Tool, What It Does, and Why You Probably Do Not Need a Formal Diagnosis

For readers who recognize themselves or someone close to them in any of what has been described above, I have built a screening instrument that combines three of the best-validated self-report measures available in the adult autism literature: the AQ-50 developed by Simon Baron-Cohen and colleagues at the Cambridge Autism Research Centre, the RAADS-R developed by Riva Ariella Ritvo and the international validation collaboration, and the CAT-Q developed by Laura Hull and colleagues at University College London.

The AQ-50 measures the visible behavioral expression of autistic features in five domains including social skills, attention switching, attention to detail, communication, and imagination, and it produces a score between zero and fifty with a screening threshold at thirty-two. The RAADS-R is a more comprehensive eighty-item instrument that explicitly distinguishes between current and childhood experiences of autistic features across four domains, and was developed specifically for the adult population that historically slipped through childhood diagnostic processes. The CAT-Q measures the active masking and compensation that characterizes the population most likely to have been missed by earlier screening tools.

A profile in which the AQ-50 is low, the RAADS-R is moderate, and the CAT-Q is very high is a classic late-diagnosis masking profile, in which the surface behavioral expression has been suppressed by years of compensatory effort while the underlying experience remains autistic at its core, and this is precisely the pattern that conventional clinical interviews miss most often.

The question of whether a formal diagnosis is worth pursuing, after the screening has produced a result that points toward an autistic profile, is one I want to address directly because the answer is more complicated than either the medical establishment or the autism advocacy community typically acknowledges. In Germany, autism is classified under the F84 category of the ICD-10, which means that a formal diagnosis becomes part of the individual’s permanent medical record, with implications for life insurance, for certain forms of professional licensing, and for custody proceedings in some jurisdictions. My own view, formed across years of watching what happens to people who pursue formal diagnosis without adequate preparation, is that for many high-functioning adults the cost-benefit calculation does not clearly favor formal diagnosis, and that the self-knowledge that comes from understanding one’s own neurology is more valuable than the bureaucratic recognition of that neurology.

The Anthropological Argument, and Why I Think We Are Looking at Something the Field Has Not Yet Named

I want to close with a position that I hold with some conviction but that I want to label clearly as a position rather than as a settled scientific claim, because the evidence supports it without quite establishing it. The position is that autism is best understood not as a disorder, not as a disease, and not as a developmental error, but as an early sample of what the next phase of human cognitive evolution looks like, an emergent variant whose features include extraordinary capacity for sustained attention, deep pattern recognition, resistance to social-emotional cascades that compromise judgment under pressure, and a relationship to information and to physical reality that is, in important ways, better suited to the kind of world that human civilization is now constructing for itself than the more typical neurology that the species has carried for the past several hundred thousand years.

The case for this position runs through several lines of evidence that converge in a way I find difficult to dismiss. The high heritability tells us that what we are looking at is an inherited cognitive architecture rather than an environmental insult. The rising prevalence, even after we discount the substantial portion attributable to better diagnosis, tells us that something is happening at the level of the population. The pattern of cognitive strengths, including pattern recognition, sustained attention, technical precision, and operational composure under genuine stress, maps with unusual precision onto the cognitive demands of the contemporary technical, scientific, and engineering economy. And the deep mechanistic findings, the synaptic protein variants, the chromatin remodeling genes, the configurations of the autonomic nervous system, all point toward a coherent biological type rather than toward a collection of unrelated developmental accidents.

If this reading is correct, then the conventional clinical framework that treats autism as something to be corrected, accommodated, or medicated into compliance with the surrounding population is not merely inadequate, it is actively counterproductive. What this neurology requires from the surrounding society is not pharmacological suppression and not behavioral retraining, it is recognition, accommodation, and the construction of social and professional environments that allow the underlying cognitive architecture to do what it is genuinely good at, while reducing the environmental loads that exhaust it.

Acceptance of the homo genius variant as a legitimate part of the human cognitive distribution, rejection of the medication-first response to its presentation, recognition of the masking and burnout phenomena that emerge from prolonged environmental mismatch, and the construction of clinical and professional infrastructure capable of supporting rather than suppressing this neurology are all changes that the next decade of medical and social development will need to take seriously. The autistic individuals walking through your office, your hospital, your school, your courtroom, your engineering team, are not broken versions of the typical brain that need to be repaired. They are, in some non-trivial fraction of cases, an early sample of the brain that the next several centuries of human civilization are going to need to be able to produce reliably if the species is going to continue to navigate the technical, informational, and ecological pressures that its own cleverness has now placed in front of it. The medical establishment has not yet noticed this. It will have to.

This article is intended for general informational purposes and represents the author’s analysis of publicly available scientific literature. Nothing in this article constitutes medical advice, and the screening instrument referenced at rauscher.xyz/autism is not a substitute for clinical assessment by a qualified diagnostician in cases where formal diagnosis is being considered.

References

• Baron-Cohen, S., Wheelwright, S., Skinner, R., Martin, J., & Clubley, E. (2001). The autism-spectrum quotient (AQ): Evidence from Asperger syndrome/high-functioning autism, males and females, scientists and mathematicians. Journal of Autism and Developmental Disorders, 31(1), 5-17.
• Bernier, R., Golzio, C., Xiong, B., et al. (2014). Disruptive CHD8 mutations define a subtype of autism early in development. Cell, 158(2), 263-276.
• Centers for Disease Control and Prevention, Autism and Developmental Disabilities Monitoring (ADDM) Network, Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years, surveillance summaries 2020 and 2022.
• Global Burden of Disease Collaborative Network (2024). Global, regional, and national burden of autism spectrum disorder: trends and decomposition analysis from 1990 to 2021, and projections for 2045.
• Higgins, J. M., Arnold, S. R., Weise, J., Pellicano, E., & Trollor, J. N. (2021). Defining autistic burnout through experts by lived experience. Autism, 25(8), 2356-2369.
• Hull, L., Mandy, W., Lai, M.-C., Baron-Cohen, S., Allison, C., Smith, P., & Petrides, K. V. (2019). Development and validation of the Camouflaging Autistic Traits Questionnaire (CAT-Q). Journal of Autism and Developmental Disorders, 49(3), 819-833.
• Hull, L., Petrides, K. V., Allison, C., Smith, P., Baron-Cohen, S., Lai, M.-C., & Mandy, W. (2017). “Putting on my best normal”: Social camouflaging in adults with autism spectrum conditions. Journal of Autism and Developmental Disorders, 47(8), 2519-2534.
• Inserra, A., De Gregorio, D., & Gobbi, G. (2022). Evaluating the potential use of serotonergic psychedelics in autism spectrum disorder. Frontiers in Pharmacology, 13, 770422.
• Leblond, C. S., et al. (2024). A genetic bridge between medicine and neurodiversity for autism. Annual Review of Genetics.
• Phung, J., Penner, M., Pirlot, C., & Welch, C. (2021). What I wish you knew: Insights on burnout, inertia, meltdown, and shutdown from autistic youth. Frontiers in Psychology, 12, 741421.
• Raymaker, D. M., Teo, A. R., Steckler, N. A., Lentz, B., Scharer, M., Delos Santos, A., Kapp, S. K., Hunter, M., Joyce, A., & Nicolaidis, C. (2020). “Having all of your internal resources exhausted beyond measure and being left with no clean-up crew”: Defining autistic burnout. Autism in Adulthood, 2(2), 132-143.
• Ritvo, R. A., Ritvo, E. R., Guthrie, D., Ritvo, M. J., Hufnagel, D. H., McMahon, W., et al. (2011). The Ritvo Autism Asperger Diagnostic Scale-Revised (RAADS-R): A scale to assist the diagnosis of autism spectrum disorder in adults. Journal of Autism and Developmental Disorders, 41(8), 1076-1089.
• Sandin, S., Lichtenstein, P., Kuja-Halkola, R., Hultman, C., Larsson, H., & Reichenberg, A. (2017). The heritability of autism spectrum disorder. JAMA, 318(12), 1182-1184.
• Tick, B., Bolton, P., Happe, F., Rutter, M., & Rijsdijk, F. (2016). Heritability of autism spectrum disorders: A meta-analysis of twin studies. Journal of Child Psychology and Psychiatry, 57(5), 585-595.
• Wink, L. K., Reisinger, D. L., Horn, P., Shaffer, R. C., O’Brien, K., Schmitt, L., Dominick, K. R., Pedapati, E. V., & Erickson, C. A. (2021). Brief report: Intranasal ketamine in adolescents and young adults with autism spectrum disorder, a randomized double-blind placebo-controlled trial. Journal of Autism and Developmental Disorders, 51(4), 1392-1399.
• World Health Organization. Autism – key facts (updated 2023).